Company intelligence / Profile preview

Laboratorio Elea

Los Polvorines, Buenos Aires, Argentinaelea.com ↗

Ownership: Private
Development stage: Other

Overview

Laboratorio Elea has over eight decades of experience developing and commercializing medicines across most major therapeutic areas. It was the first Argentine company to launch a monoclonal antibody in the market and has since introduced biosimilars such as Rituximab and Bevacizumab. The company maintains a strong presence in oncology and biotechnology with more than 600 products overall.

Therapeutic areas: NeurologyPulmonologyInfectious DiseasesOphthalmologyMen's HealthCardiovascularOncologyGastroenterologyOtherRheumatologyWomen's Health
Modalities: Small moleculesMonoclonal antibodies (mAbs)Recombinant proteinsSynthetic peptidesTherapeutic vaccines
Industry: Biotech

Drug pipeline

3 assets

Pembrox

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Laboratorio Elea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Laboratorio Elea.

Explore the full profile